Compugen (CGEN) And Tel Aviv University Announce Unique Predictive Method For Identifying Alternative Splicing In The Human Genome; New Method Does Not Require EST Or Microarray Data
10/19/2005 5:11:58 PM
Compugen Ltd. (Nasdaq:CGEN) and Tel Aviv University announced today the development of a new method for identifying alternative splicing without the need for either EST (Expressed Sequence Tag) data or microarray experimentation. Hundreds of novel predicted proteins discovered to date using this new predictive method are currently undergoing initial assessment for possible addition to Compugen's growing therapeutic and diagnostic pipeline, and for licensing. The work, which was published in Genome Research (Volume 14, Pages 1617-1623), was a collaborative effort between Compugen's scientists and Professors Ron Shamir and Gil Ast from Tel Aviv University.
comments powered by